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Abstract
Background: The cerebellum is an important site for cortical demyelination in multiple sclerosis, but the functional
significance of this finding is not fully understood.
Objective: To evaluate the clinical and cognitive impact of cerebellar grey-matter pathology in multiple sclerosis patients.
Methods: Forty-two relapsing-remitting multiple sclerosis patients and 30 controls underwent clinical assessment including
the Multiple Sclerosis Functional Composite, Expanded Disability Status Scale (EDSS) and cerebellar functional system (FS)
score, and cognitive evaluation, including the Paced Auditory Serial Addition Test (PASAT) and the Symbol-Digit Modalities
Test (SDMT). Magnetic resonance imaging was performed with a 3T scanner and variables of interest were: brain white-
matter and cortical lesion load, cerebellar intracortical and leukocortical lesion volumes, and brain cortical and cerebellar
white-matter and grey-matter volumes.
Results: After multivariate analysis high burden of cerebellar intracortical lesions was the only predictor for the EDSS (p,
0.001), cerebellar FS (p = 0.002), arm function (p = 0.049), and for leg function (p,0.001). Patients with high burden of
cerebellar leukocortical lesions had lower PASAT scores (p = 0.013), while patients with greater volumes of cerebellar
intracortical lesions had worse SDMT scores (p = 0.015).
Conclusions: Cerebellar grey-matter pathology is widely present and contributes to clinical dysfunction in relapsing-
remitting multiple sclerosis patients, independently of brain grey-matter damage.
Citation: Damasceno A, Damasceno BP, Cendes F (2014) The Clinical Impact of Cerebellar Grey Matter Pathology in Multiple Sclerosis. PLoS ONE 9(5): e96193.
doi:10.1371/journal.pone.0096193
Editor: Pablo Villoslada, Institute Biomedical Research August Pi Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Spain
Received December 6, 2013; Accepted April 3, 2014; Published May 2, 2014
Copyright:  2014 Damasceno et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo (FAPESP)(grants numbers 2010/00885-4 and 2013/07559-3). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: alfredodamasceno@hotmail.com
Introduction
In recent years, several neuroimaging studies have shown diffuse
grey matter (GM) damage in multiple sclerosis (MS) patients,
involving both cortical and subcortical structures, such as the
spinal cord and cerebellum. Indeed, modern neuropathological
research confirmed these findings and proposed the cerebellum as
an important location for cortical demyelination in MS, particu-
larly in those with primary or secondary progressive disease.[1–3]
Similar types of cortical lesions, as described in the forebrain, are
also seen in the cerebellum, such as intracortical and leukocortical.
These lesions are also characterized by complete demyelination
with relative preservation of neurons and axons.[1,3] However,
the functional significance of these lesions is not completely clear.
Moreover, besides its key role in motor function, increasing
evidence supports a significant function of the cerebellum in
cognition, dependent upon the existence of different anatomical
connections between high-level cortical regions, which may also be
involved in MS lesions.[3–5] Although there are some studies
reporting association between MRI atrophy measures and clinical
performance, very few evaluated the clinical and cognitive impact
of these cortical lesions.[6–8] Therefore, in this study, we
evaluated the influence of cerebellar GM pathology, as measured
by MRI, in clinical and cognitive functions in a group of patients
with relapsing remitting MS, addressing relative contributions of
cerebellar cortical and white-matter (WM) atrophy, and also
cerebellar leukocortical and intracortical lesions.
Methods
Subjects
We prospectively and consecutively enrolled 42 patients with a
relapsing-remitting MS diagnosis according to the revised 2005
McDonald criteria,[9] and 30 age- and gender-matched healthy
control subjects for comparison as a control group. All individuals
were evaluated at the MS Center of UNICAMP University
Hospital, Campinas, Brazil. All patients were clinically stable (no
relapse in the previous three months), with age ranging from 20 to
50 years-old, and on treatment with disease-modifying drugs
(Table 1). Exclusion criteria were: progressive course, fulfillment of
diagnostic criteria for neuromyelitis optica, EDSS .5.0, any pre-
existing condition known to be associated with brain atrophy or
any relapse or steroid therapy within three months preceding the
clinical and MRI evaluation.
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Ethics Statement
The study was approved by the ethics committee of the faculty
of medical sciences of University of Campinas and all individuals
provided written informed consent.
Clinical assessment/Outcome measures
Neurological clinical examination included: assessment of leg
function by means of the timed twenty-five foot walk (T25FW) and
arm function with the nine-hole peg test (9HPT) for all
participants. We also measured overall disability with the
Expanded Disability Status Scale (EDSS) for all patients and the
cerebellar Functional System (FS) score.[10] Cognitive evaluation
included the Paced Auditory Serial Addition Test (PASAT) and
Symbol Digit Modalities Test (SDMT) for all individuals. Each of
these tests was considered different outcome measures.
Magnetic resonance imaging
MRI scans for all subjects were acquired on a 3T scanner
(Phillips Achieva-Intera). The study protocol consisted of: fluid
attenuated inversion recovery (FLAIR) – acquired in the axial
plane with 3 mm slice thickness (TR 11000 ms, TI 2800 ms, TE
125 ms, matrix 3286210, gap 0, FOV 23618 cm, flip angle 90u;
in-plane resolution 0.7 mm60.85 mm); double inversion recovery
(DIR) - acquired in the axial plane with 3 mm slice thickness (TR
11000 ms, TI 3400 ms, TE 50 ms, delay 325 ms, matrix
3286210, gap 3, FOV 23618 cm, flip angle 90u; in-plane
resolution 0.7 mm60.85 mm) and a volumetric (three-dimension-
al) T1 gradient echo images - acquired in the sagittal plane with
1 mm slice thickness (TR 7.0 ms, TE 3.2 ms, matrix 2406 240,
FOV 24 6 24 cm, flip angle 8u; in-plane resolution
1.0 mm61.0 mm).
Image Analysis
Brain – WM. Brain WM lesion load (WML) was quantified
on FLAIR sequences, blinded to clinical data, using the freely
available Medical Image Processing, Analysis, and Visualization
(MIPAV) software package developed at the Center for Informa-
tion Technology, National Institutes of Health.[11] The intrarater
reliability between brain WML quantification was assessed using
intra-class correlation (with three sets of data points; ICC=0.972);
Infratentorial lesions were not included in brain WML.
Brain – GM. Brain cortical lesions were identified and scored
on DIR sequences, blinded to clinical data, in accordance to
consensus recommendation, [12] and accurately controlled for
artifacts. Lesion volume was quantified using the MIPAV software.
The intrarater reliability between lesion quantification was
assessed using intra-class correlation (with three sets of data
points; ICC=0.896). Brain cortical volume evaluation was
performed on volumetric T1 gradient echo images by means of
the FreeSurfer v5.1 image analysis suite, available online (http://
surfer.nmr.mgh.harvard.edu/) (left + right hemispheres volumes),
as described elsewhere.[13–15] All images were systematically
controlled for errors and artifacts.
Cerebellum – WM. Presence of cerebellar WM lesions was
analyzed on both FLAIR and DIR sequences. Cerebellar WM
volume evaluation was performed on volumetric T1 gradient echo
images by means of the FreeSurfer v5.1 image analysis suite,
available online (http://surfer.nmr.mgh.harvard.edu/) (left + right
hemispheres volumes), as described elsewhere.[13–15] All images
were systematically controlled for errors and artifacts.
Cerebellum – GM. Cerebellar GM lesions were identified
and scored on DIR sequences, blinded to clinical data, in
accordance to consensus recommendation,[12] and accurately
controlled for artifacts. Lesion volume was quantified using the
MIPAV software. Cerebellar GM lesions were further classified as
being intracortical or leukocortical (Figure 1):
Intracortical - when lesion borders remained completely within
the cortex.
Leukocortical - when lesions involved the WM/GM junction.
The intrarater reliability between lesion quantification was
assessed using intra-class correlation (with three sets of data points;
ICC=0.949 for both);
Cerebellar GM volume evaluation was performed on volumet-
ric T1 gradient echo images by means of the FreeSurfer v5.1
image analysis suite, available online (http://surfer.nmr.mgh.
harvard.edu/) (left + right hemispheres volumes), as described
elsewhere.[13–15] All images were systematically controlled for
errors and artifacts.
Statistical analysis
Statistical analysis was performed using the Statistical Package
for the Social Sciences (SPSS, Version 20.0., SPSS Inc, Chicago,
Illinois).
Comparisons on brain and cerebellar volumes were analyzed by
the General Linear Model (GLM) univariate analyses of variance
procedure, with gender and total intracranial volume as covari-
ates. Group comparisons on clinical and cognitive tests were also
performed with GLM with number of years of education as
covariate.
Spearman correlation analyses were performed to test the
associations between clinical and MRI factors and clinical/
cognitive outcomes. We also performed partial correlations of
cerebellar cortical lesions, EDSS, and cerebellar FS score
controlling for brain cortical lesions and brain cortical volume
(as covariates).
A stepwise multivariate linear regression analysis was performed
initially to assess a possible relative contribution of demographic
variables (age, disease duration, years of education and gender) in
Figure 1. Cerebellar intracortical and leukocortical lesions. Axial
double inversion recovery images from relapsing-remitting MS patients
showing intracortical (long arrows, A and B) and leukocortical lesions
(short arrows, C and D).
doi:10.1371/journal.pone.0096193.g001
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clinical (EDSS, cerebellar FS, 9HPT and T25FW) and cognitive
outcomes (PASAT and SDMT) and then, the same procedure was
used to assess the relative contribution of MRI factors (cerebellar
intracortical and leukocortical lesions, brain WML, brain cortical
lesions, brain cortical volume, and cerebellar WM and GM
volumes) in the same clinical and cognitive outcomes. Given a non
normal distribution of cerebellar and brain lesion volumes, these
variables were dichotomized to low/high burden of lesions based
on the mean value (cerebellar intracortical and leukocortical
lesions $ 0.05 cm3; brain cortical lesions $ 1 cm3; and brain
WML $ 3 cm3).
We also assessed the relative contribution of disease duration,
age, and MRI lesions (brain and cerebellum) to cerebellar GM and
WM volume. Backward stepwise analyses were conducted (Wald
statistic) with a p value for entry of 0.05 and a p value for removal
of 0.1. The level of significance was p,0.05.
Results
Clinical and MRI characteristics
Clinical and MRI features are shown in Table 1. Cerebellar
intracortical and/or leukocortical lesions were observed in 53.8%
of the patients (leukocortical in 43.6% and intracortical in 33.3%).
Cerebellar WM lesions were found in 62.5% of the patients
(Overall, 70.7% of the patients had cerebellar WM and/or GM
lesions).
Patients and controls were similar regarding age and gender
distribution, but had different years of education. Therefore, group
comparisons on clinical and cognitive tests were also performed
with number of years of education as covariate. There was no
difference regarding gender or presence of oligoclonal bands on
performances of clinical/cognitive tests or volumes of brain/
cerebellar lesions, except for the T25FW test, where women took
longer than men (4.99 vs. 4.20 seconds, p = 0.011).
Outcome measures
Clinical. Patients with high load of cerebellar leukocortical
lesions had similar scores on clinical outcomes when compared to
those with lower burden of these lesions. Conversely, patients with
high burden of cerebellar intracortical lesions performed the
T25FW and 9HPT tests at a slower pace (5.49 vs. 4.37 seconds,
p,0.001; and 25.22 vs. 21.94 seconds, p = 0.025, respectively) and
had higher scores on the cerebellar FS and total EDSS (1.25 vs.
0.33, p = 0.007; and 2.92 vs. 1.74, p = 0.001, respectively)
(Figure 2).
On correlation analysis, cerebellar leukocortical lesions were
significantly associated with cerebellar FS score while cerebellar
intracortical lesions were related to all clinical outcomes (Table 2).
We performed partial correlations of cerebellar cortical lesions
and EDSS controlling for brain cortical lesions and brain cortical
volume (as covariates), and the correlation was still significant
(R=0.491, p = 0.002). This was also true for the FS cerebellar
score (R=0.463, p = 0.004).
Table 1. Clinical and MRI data.
RRMS patients Controls Between-Subjects Comparisons *
Sex: no. (%) Female/Male 32 (76.2)/10 (23.8) 23 (76.7)/7 (23.3) 0.596
Age: years 30.5266.60 29.5267.52 0.352
Education: years 13.6961.83 15.1860.77 0.001
Disease duration: years 6.4064.94 NA NA
Treatment: no. patients (%) IM IFN b-1a/SC IFN
b-1b/SC IFN b-1a/SC GA
14 (18.4)/15 (19.7)/7 (9.2)/6 (7.9) NA NA
EDSS score 2.5 (0 – 4) NA NA
FS cerebellar 0 (0 – 3) NA NA
9HPT: seconds 22.9264.43 17.8361.49 F = 17.24; p,0.001
T25FW: seconds 4.8060.85 4.0560.67 F = 7.94; p = 0.001
PASAT: raw score 33.02613.01 43.6669.44 F = 13.20; p,0.001
SDMT: raw score 50.38 6 13.31 65.14611.37 F = 16.75; p,0.001
Cerebellar GM volume: cm3 92.77612.92 94.376611.43 F = 15.63; p,0.001
Cerebellar WM volume: cm3 27.37 6 4.71 29.0363.52 F = 3.45; p = 0.021
Brain cortical volume: cm3 432.19641.52 440.83635.14 F = 9.27; p,0.001
Cerebellar intracortical lesions: cm3 0.0560.08 NA NA
Cerebellar intracortical lesions: no. (range) 0.5460.91 (0–4) NA NA
Cerebellar leukocortical lesions: cm3 0.0560.10 NA NA
Cerebellar leukocortical lesions: no. (range) 0.6961.00 (0–4) NA NA
Brain WM lesions volume: cm3 6.1969.19 NA NA
Brain cortical lesions: cm3 0.8560.87 NA NA
Expressed are mean values and standard deviation, except for EDSS and FS cerebellar scores, where a median and range are provided.
9HPT: nine-hole peg test; EDSS: Expanded Disability Status Scale; FS: functional system; GA: glatiramer acetate; GM: grey-matter; IFN: interferon; IM: intramuscular; NA:
not applicable; PASAT: Paced Auditory Serial Addition Test; RRMS: relapsing-remitting multiple sclerosis; SC: subcutaneous; SDMT: Symbol Digit Modalities Test; T25FW:
timed twenty-five foot walk test; WM: white-matter.
* Group comparisons were performed with Mann-Whitney U tests for age and education; Fisher’s exact test for gender distribution; and the General Linear Model with
gender and total intracranial volume as covariates for volumes comparisons and with education as covariate for clinical tests performances.
doi:10.1371/journal.pone.0096193.t001
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After multivariate analysis, age, disease duration, years of
education, and gender were not related to clinical outcomes,
except for the T25FW test, where gender, disease duration and
age were independent predictors (b=0.75, 95% CI 0.27 to 1.23,
p = 0.003; b=20.05, 95% CI 20.095 to 20.007, p = 0.025; and
b=0.076, 95% CI 0.043 to 0.108, p,0.001, respectively).
High burden of cerebellar intracortical lesions was the only
independent predictor for the EDSS (b=1.109, 95% CI 0.575 to
1.642, p,0.001), cerebellar FS score (b=0.904, 95% CI 0.349 to
1.459, p = 0.002), and to the 9HPT time (b=3.107, 95% CI 0.011
to 6.203, p = 0.049).
For the T25FW time, high burden of cerebellar intracortical
lesions and brain cortical volume remained as independent
predictors but only the first was statistically significant
(b=1.062, 95% CI 0.607 to 1.518, p,0.001, and b=20.005,
95% CI 20.009 to 0.000, p = 0.071). When those clinical factors
found to be independent predictors of this test (age, disease
duration and gender) were included in the model, cerebellar
intracortical lesions still remained as an independent predictor
(b=0.965, 95% CI 0.59 to 1.34, p,0.001).
Cognitive. Patients with high burden of cerebellar leukocor-
tical lesions had lower scores on the PASAT test (25.25 vs. 36.67,
p = 0.013), while patients with greater volumes of cerebellar
intracortical lesions had lower scores on the SDMT (43.25 vs.
53.18, p = 0.015) (Figure 2).
On correlation analyses, cerebellar leukocortical lesions were
significantly associated with the PASAT score but cerebellar
intracortical lesions were not related to cognitive outcomes
(Table 2).
In multivariate analysis, number of years of education was the
only clinical factor related to SDMT (b=3.102, 95% CI 0.996 to
5.209, p= 0.005) and to PASAT score (b=2.930, 95% CI 0.857 to
5.002, p = 0.007).
For the PASAT score, high burden of cerebellar leukocortical
lesions (b=26.066, 95% CI 212.296 to 0.165, p= 0.056), WML
(b=214.610, 95% CI 220.909 to 28.310, p,0.001), and brain
cortical volume (b=0.083, 95% CI 0.015 to 0.152, p= 0.018)
remained in the model.
Both high burden of cerebellar intracortical lesions and brain
WML showed a trend to predict SDMT score (b=27.869, 95%
CI 216.843 to 1.106, p = 0.084, and b=27.837, 95% CI 2
16.371 to 0.698, p = 0.071, respectively).
Cerebellar atrophy
There was a tendency to cerebellar intracortical lesions predict
cerebellar GM volume (b=28.55, 95% CI 217.74 to 0.65,
p = 0.068). High burden of cerebellar leukocortical lesions was the
only independent predictor to cerebellar WM volume (b=23.65,
95% CI 26.93 to 20.37, p= 0.030).
Discussion
This in vivo MRI study confirms a major role of cerebellar GM
pathology in clinical disability of MS patients, and strengthens
findings from previous research. [8] Cerebellar GM involvement
in this disease has been clearly demonstrated in a number of
neuropathological studies, concerning both cortical lesions and
atrophy.[3] Alike the forebrain, similar types of cortical lesions are
seen in the cerebellum, mainly extending over several folia.[1]
However, pathological studies so far yielded little information
about the clinical significance of cerebellar GM pathology and one
study found no association between cerebellar cortical demyelin-
ation and clinical factors (i.e. age, gender and disease duration).[1–
3]
MRI in-vivo visualization of cortical pathology provides a better
opportunity to assess such clinical significance but lesions in the
GM are mostly undetectable with traditional MRI sequences.[3]
GM atrophy measurements can be done with 3D MRI
acquisitions using different types of software. Therefore, this
approach has been used by several studies which documented a
progressive loss of brain parenchyma, starting at the earliest stages
and continuing throughout the long course of the disease.[3] In
particular for the cerebellum, using voxel-based morphometry,
significant correlations were found between cerebellar volume
estimates and clinical metrics as measured by 9HPT and EDSS
cerebellar functional score.[6] On the other hand, Anderson et al,
on a comprehensive evaluation of cerebellar damage using
diffusion tractography and volumetric analysis, found that
cerebellar WM volume was associated with 9HPT score in
patients with primary progressive MS, independently of cerebellar
GM volume.[16] We found significant correlations between
cerebellar WM/GM volumes and clinical dysfunction (cerebellar
FS) and information processing speed performance (PASAT) in
patients with relapsing-remitting MS, supporting findings from
recent research stressing the cerebellar role in cognitive functions
and notably sequencing abilities.[4,5] However, these associations
with cerebellar volumes were not present after multivariate
analysis, where cerebellar cortical lesions were more predictive.
Posterior fossa lesions are typical in MS but their visualization
presents challenges for neuroimaging. Conventional MRI tech-
niques can leave some infratentorial lesions undetected, and
especially cerebellar GM lesions. Recently, a more sensitive MRI
acquisition sequence, known as DIR, has become available and
has been reported to identify significantly more inflammatory
lesions in the infratentorial brain even compared with the T2
turbo spin-echo sequence. [3,17] Although some studies have
found significant associations between brain cortical lesions and
cognitive dysfunction using this sequence, [3,18] very few studies
evaluated the clinical impact of cerebellar GM lesions. Calabrese et
al evaluated the relative contribution of cerebellar cortical lesions
in multivariate analysis and found them to be independent
predictors of cerebellar disability. They also found cerebellar GM
volume to be independent predictor of both cerebellar disability
and EDSS score.[8] In accordance, we found that cerebellar
intracortical lesions are predictors for both arm and leg
dysfunction, and also for cerebellar and overall disability as
measured by the EDSS, independently of brain cortical lesions or
volume. As an example, high burden of cerebellar intracortical
lesions increased T25FW time in one second, 9HPT time in three
seconds and the EDSS score in one step.
We also aimed to discriminate the role of cerebellar intracortical
and leukocortical lesions. Intracortical lesions were strongly related
to clinical dysfunction and had a milder association with SDMT
test performance, while leukocortical lesions were associated with
the PASAT test score and cerebellar WM atrophy. Intracortical
lesions represent around 50% of GM plaques in the cerebellum.[2]
Some demyelinated plaques in the cerebellar cortex are also found
in continuity with demyelination in the subcortical WM and
sometimes associated with large WM plaques,[1] what may
explain the contribution of cerebellar leukocortical lesions to
Figure 2. Burden of cerebellar intracortical lesions and clinical/cognitive outcomes. Box plots comparing patients with high and low
burden (. 0.05 cm3 or,0.05 cm3) of cerebellar intracortical lesions on clinical (A – D) and cognitive outcomes (E, F).
doi:10.1371/journal.pone.0096193.g002
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cerebellar WM atrophy found in our study. Moreover, involve-
ment of both GM and WM may disrupt important cerebello-
cortical loops known to be involved in attention and other
cognitive functions.[4,5] Interestingly, Sastre-Garriga et al has
recently shown with functional MRI an important cerebellar
activation when PASAT test was used as paradigm.[19]
Although DIR MRI may improve detection of cortical lesions
up to five times when compared with a conventional T2-weighted
sequence, the vast majority are still missed by this technique,
especially subpial lesions which may also have important
contribution to clinical and cognitive dysfunction in MS
patients.[3] Another disadvantage is its low signal-to-noise ratio,
resulting in low agreement between observers. Therefore, some
lesions considered as intracortical may in fact be leukocortical and
vice-versa. Moreover, we have not included cerebellar WM lesions
volumetry in our analysis and, therefore, we cannot discriminate if
cerebellar leukocortical lesions influence is predominantly due to
its GM or WM involvement. Future studies associating greater
MRI field strengths and novel/improved sequences, such as 3D-
DIR or phase sensitive inversion recovery may overcome this
gap.[3,20,21]
In conclusion, cerebellar GM is widely affected in relapsing-
remitting MS patients. Cerebellar GM pathology strongly
contributes to clinical dysfunction in relapsing-remitting MS
patients and also to information processing speed deficits in a
lesser extent, independently of brain cortical lesions or volume.
This damage can be monitored in-vivo with MRI. Further work is
required to better characterize GM plaques and to assess its
contribution to long term disability.
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